Overview

Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga

Status:
Completed
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether in patients with early type 2 diabetes, a short-term intensive metabolic intervention comprising Forxiga, metformin, basal insulin glargine and lifestyle approaches will be superior to standard diabetes therapy in achieving sustained diabetes remission.
Phase:
Phase 4
Details
Lead Sponsor:
Population Health Research Institute
Collaborator:
AstraZeneca
Treatments:
Dapagliflozin
Insulin
Insulin Glargine
Insulin, Globin Zinc
Metformin